ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting
June 22 2020 - 9:01AM
Business Wire
Next Generation FRα-Targeting ADC Engineered to Maximize
Potential Clinical Benefit for Patients with Lower FRα
Expression
Potent Anti-Tumor Activity Exhibited in Ovarian Cancer and Other
Tumor Types Regardless of FRα Expression Level
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced preclinical data for its next generation
anti-folate receptor alpha (FRα) ADC, IMGN151, which is being
investigated in tumors with a broad range of FRα expression. The
findings were shared via poster presentation at the virtual
American Association for Cancer Research (AACR) Annual Meeting
II.
“Engineered to include multiple antibody and linker-payload
innovations, IMGN151 targets tumors with a broad range of FRα
expression,” said Eric Westin, MD, Vice President of Clinical
Development and Translational Sciences at ImmunoGen. “IMGN151
demonstrated enhanced anti-tumor activity in both in vitro and in
vivo preclinical models, with complete regression of human tumor
xenograft models induced in those with high, medium, and low levels
of FRα expression. Based on these data, we look forward to
exploring IMGN151 in the clinic in multiple FRα-positive epithelial
malignancies, including ovarian, endometrial, triple negative
breast, and non-small cell lung cancer.”
IMGN151 PRECLINICAL DATA Poster Presentation, Abstract
2890
IMGN151 comprises an asymmetric, bivalent, biparatopic antibody
targeting two independent epitopes of FRα, linked to a highly
potent maytansinoid derivative, DM21, via a cleavable peptide
linker with enhanced stability, longer half-life, and increased
bystander activity. The average drug per antibody ratio is 3.5.
IMGN151 activity was characterized against cell lines and xenograft
models with a wide range of FRα expression and compared to
mirvetuximab soravtansine (IMGN853). Cell lines and xenograft
models originated from ovarian, endometrial, breast, and cervical
cancer.
Key findings include:
- The protease-cleavable linker deployed in IMGN151 improves
stability and ADC exposure; as compared to IMGN853, pharmacokinetic
studies in cynomolgus monkeys showed increased ADC half-life by 60
hours and conjugate exposure in vivo by 40%.
- The IMGN151 biparatopic format boosted antibody binding events
and DM21 payload delivery in tumor cell lines; the increased
payload delivery and greater membrane permeability of DM21 enhanced
bystander killing activity.
- In vitro, IMGN151 was more active against FRα-positive cell
lines, with the most pronounced effect in cells with low to medium
levels of FRα.
- In vivo, IMGN151 demonstrated better activity over IMGN853
against low and medium levels of FRα, and equivalent activity to
IMGN853 against FRα high tumors with lower effective dose; all
tested doses were well tolerated.
Additional information can be found at www.aacr.org.
ABOUT IMGN151
IMGN151 is a next-generation ADC, designed to address the unmet
needs of cancer patients with tumor types expressing lower levels
of folate receptor alpha (FRα). IMGN151 comprises an asymmetric,
bivalent, biparatopic antibody targeting two independent epitopes
of FRα, linked to a highly potent maytansinoid derivative, DM21,
via a cleavable peptide linker with enhanced stability, longer
half-life, and increased bystander activity.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates (ADCs) to improve outcomes for cancer patients. By
generating targeted therapies with enhanced anti-tumor activity and
favorable tolerability profiles, we aim to disrupt the progression
of cancer and offer our patients more good days. We call this our
commitment to “target a better now.”
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
FORWARD LOOKING STATEMENTS
This press release includes forward-looking statements based on
management's current expectations. These statements include, but
are not limited to, ImmunoGen’s expectations related to: the
occurrence, timing, and outcome of potential pre-clinical,
clinical, and regulatory events related to ImmunoGen’s product
candidates; and the presentation of pre-clinical and clinical data
on ImmunoGen’s product candidates. For these statements, ImmunoGen
claims the protection of the safe harbor for forward-looking
statements provided by the Private Securities Litigation Reform Act
of 1995. Various factors could cause ImmunoGen’s actual results to
differ materially from those discussed or implied in the
forward-looking statements, and you are cautioned not to place
undue reliance on these forward-looking statements, which are
current only as of the date of this release. Factors that could
cause future results to differ materially from such expectations
include, but are not limited to: the timing and outcome of
ImmunoGen’s pre-clinical and clinical development processes; the
difficulties inherent in the development of novel pharmaceuticals,
including uncertainties as to the timing, expense, and results of
pre-clinical studies, clinical trials, and regulatory processes;
ImmunoGen’s ability to financially support its product programs;
risks and uncertainties associated with the scale and duration of
the COVID-19 pandemic and resulting impact on ImmunoGen’s industry
and business; and other factors more fully described in ImmunoGen’s
Annual Report on Form 10-K for the year ended December 31, 2019 and
other reports filed with the Securities and Exchange
Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200622005143/en/
INVESTOR RELATIONS AND MEDIA CONTACTS ImmunoGen Courtney
O’Konek 781-895-0600 courtney.okonek@immunogen.com
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024